Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520530 | 0.88 | TSHR (0.58) | TSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL9419439 | 0.88 | KDM4E (0.43) | TSHRL3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL7103779 | 0.87 | KMT2A (0.47) | TSHRL3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL4575280 | 0.86 | TSHR (0.65) | TSHRKMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL23347194 | 0.86 | TSHR (0.45) | TSHRL3MBTL1KMT2ARAB9AALDH1A1 | |
| Laurocapram SCHEMBL28259860 | 0.84 | GAA (0.47) | TSHRL3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL19119048 | 0.83 | GAA (0.43) | TSHRL3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL11670561 | 0.81 | L3MBTL1 (0.44) | TSHRL3MBTL1KMT2AMEN1RAB9A | |
| SCHEMBL2633812 | 0.81 | TSHR (0.67) | TSHRL3MBTL1KMT2AMEN1RAB9A | |
| Octadecanoic Acid Amide SCHEMBL28107856 | 0.80 | TSHR (0.53) | TSHRL3MBTL1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660857-B2 | Reuse of carpet wastes | DSM N.V. (NL) | 2003-12-09 | — | — | US | disclosed |
| EP-1257532-B1 | PROCESS FOR THE PREPARATION OF $g(e)-CAPROLACTAM | DSM IP ASSETS BV (NL) | 2003-09-10 | — | — | EP | disclosed |
| US-20030065169-A1 | Process for the preparation of epsilon-caprolactam | DSM N.V. | 2003-04-03 | — | — | US | disclosed |
| EP-1257532-A1 | PROCESS FOR THE PREPARATION OF $g(e)-CAPROLACTAM | DSM N.V. (NL) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001056984-A1 | PROCESS FOR THE PREPARATION OF ε-CAPROLACTAM | DSM N.V. (NL) | 2001-08-09 | — | — | WO | disclosed |
| EP-1122241-A1 | Process for the preparation of epsilon-caprolactam | DSM N.V. (NL) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065169-A1 | Process for the preparation of epsilon-caprolactam | MCCC2, ACMSD, PCCA | TSHR 445/4885L3MBTL1 4304/4885KMT2A 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.